PCSK9 gene expression is associated with biological processes such as lipid metabolism and inflammation. Cholesterol-lowering therapies are the gold standard for reducing the risk of cardiovascular mortality and morbidity. Administration of monoclonal antibodies (mAbs) against PCSK9 is a novel lipid-lowering therapeutic approach in adults to reduce the risk of cardiovascular disease.
Keyphrases
- cardiovascular disease
- low density lipoprotein
- gene expression
- cardiovascular events
- type diabetes
- metabolic syndrome
- dna methylation
- insulin resistance
- oxidative stress
- weight loss
- fatty acid
- cardiovascular risk factors
- genome wide
- copy number
- risk factors
- high fat diet induced
- physical activity
- coronary artery disease